Protocol Ledger

NCT03570619 · Phase II · COMPLETED

Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

Interventional Phase II clinical trial protocol NCT03570619 sponsored by University of Michigan Rogel Cancer Center in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-12-14 Enrollment: 56 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03570619
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)56 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03570619
Protocol FieldVerified Registry Value
NCT IdentifierNCT03570619
Consolidated Lead SponsorUniversity of Michigan Rogel Cancer Center
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment56 participants (ACTUAL)
Registered Start Date2018-12-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for University of Michigan Health across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI